News Release

News Release
Boehringer Ingelheim Vetmedica Inc.
Enters Into an Agreement to Sell U.S.
Feline, Canine and Rabies Vaccines
Portfolio to Elanco Animal Health
Deal Subject to FTC Approval and Successful Closing of BI/Sanofi Asset Swap
ST. JOSEPH, MO. October 5, 2016 – Boehringer Ingelheim
Vetmedica Inc. (BIVI) today announced an agreement with
Elanco U.S., Inc., a subsidiary of Eli Lilly and Company (NYSE:
LLY), to sell a portfolio of U.S. canine, feline and rabies
vaccines, as well as a fully integrated manufacturing and R&D
site, to Elanco. The sale price of $885 million includes the
estimated cost of acquired inventory. The deal is conditioned on
antitrust approval and closing of the Boehringer Ingelheim (BI)
asset swap transaction with Sanofi that was signed in June
2016.
“This agreement is an important step toward a successful
acquisition of Merial,” said Dr. Albrecht Kissel, president and
CEO of Boehringer Ingelheim Vetmedica Inc. “This was a highly
complex decision from a business and from an emotional
perspective. It was certainly not taken lightly particularly in view
of the history and significant positive developments of this
business over the past years.”
Rene Ward
Director, Public Relations and
Internal Communications
3902 Gene Field Rd.
St. Joseph, MO 64506
Phone: 816-244-7489
E-mail: rene.wardt@boehringeringelheim.com
www.bi-vetmedica.com
Julie Lux
FLM+
816-807-9972
jlux@wideopenthinking.com
“We are confident that, under Elanco’s leadership, customers
will continue to have access to these innovative vaccines and
the portfolio will have strong support,” Kissel added.
Boehringer Ingelheim News Release page 1 of 4

2
News Release
The current BIVI vaccine portfolio has experienced consistent
revenue growth over the past three years. Just this year, the
company launched two new vaccines, ULTRA TM Hybrid TM
FVRCP and ULTRA Duramune ® Lyme, both available in the
innovative 0.5mL dose developed by BIVI.
The sale to Elanco is anticipated to close by early 2017 subject
to approval by the Federal Trade Commission, and other
contingencies.
Products included within the proposed Elanco acquisition:
Canine:
Duramune ®
Duramune ® Max 5/4L
Duramune ® Max 5
Duramune ® Max 5-Cvk/4L
Duramune ® Max 5-Cvk
Duramune ® Max Pv
Duramune ® CV-K
Duramune ® Max PC
Duramune ® Adult 3
LeptoVax ® 4
LeptoVax ® 4/C
Bronchi-Shield ®
Bronchi-Shield ® ORAL
Bronchi-Shield ® III
Duramune Lyme ®
Duramune Lyme ®
Duramune Lyme ® +LeptoVax ® 4
Duramune Lyme ® +Leptovax ® 4/C
Duramune Lyme ® +Max 5/4L
Duramune Lyme ® +Max5-CvK/4L
Duramune Lyme ® +Max5-CvK
ULTRA TM Duramune ®
ULTRA TM Duramune ® DAP+4L
ULTRA TM Duramune ® DAP
ULTRA TM Duramune ® 4L
ULTRA TM Duramune ® DAP+C4L
ULTRA TM Duramune ® DAP+C
ULTRA TM Duramune ® Lyme
Boehringer Ingelheim News Release page 2 of 4

3
News Release
Feline:
Fel-O-Vax ®
Fel-O-Vax Lv-K ® III + CaliciVax ®
Fel-O-Vax ® Lv-K ®
Fel-O-Vax ® Lv-K/FIV
Fel-O-Vax ® IV+CaliciVax ®
Fel-O-Vax ® PCT+CaliciVax ®
Fel-O-Vax ® Lv-K IV+CaliciVax ®
Fel-O-Vax ® FIV
CaliciVax ®
ULTRA TM Fel-O-Vax ®
ULTRA TM Fel-O-Vax ® FVRCP+FeLV
ULTRA TM Fel-O-Vax ® FVRCP
ULTRA TM Fel-O-Vax ® FeLV
ULTRA TM Fel-O-Vax ® Dual FCV
Ultra TM Hybrid TM FVRCP
Fel-O-Guard ®
Fel-O-Guard ® Plus 3
Fel-O-Guard ® Plus 3+Lv-K
Fel-O-Guard ® Plus 4
Fel-O-Guard ® Plus 4 +Lv-K
Rabies
Rabvac ®
Rabvac ® 3
Rabvac ® 1
About Boehringer Ingelheim Vetmedica, Inc. (BIVI)
Boehringer Ingelheim Vetmedica, Inc. (BIVI), is the U.S. animal
health division of Boehringer Ingelheim GmbH. BIVI develops,
manufactures and markets novel and innovative solutions for
the prevention and treatment of disease in the cattle, equine,
pet and swine markets. BIVI is the fifth largest animal health
company in the U.S. Our U.S. headquarters is located within
the KC Animal Health Corridor in St. Joseph, Mo. We have
2,000 employees unleashing their collective passion to keep
animals healthy every day.
With more than 3,800 employees worldwide, Boehringer
Ingelheim Animal Health achieved net sales of about 1.4 billion
euros in 2015. In our research-driven Animal Health business,
Boehringer Ingelheim continually invests more than 11 percent
of net sales of the Animal Health business in R&D.
Boehringer Ingelheim News Release page 3 of 4

4
News Release
Boehringer Ingelheim is one of the world’s 20 leading
pharmaceutical companies. Headquartered in Ingelheim,
Germany, Boehringer Ingelheim operates globally through 145
affiliates and a total of some 47,500 employees. Founded in
1885, the focus of the family-owned company is on researching,
developing, manufacturing and marketing new medications of
high therapeutic value for human and veterinary medicine.
Social responsibility is an important element of the corporate
culture at Boehringer Ingelheim. This includes worldwide
involvement in social projects through, for example, the “Making
More Health” initiative while also caring for employees.
Respect, equal opportunity and reconciling career and family
form the foundation of mutual cooperation. The company also
focuses on environmental protection and sustainability in
everything it does.
For more information, please visit bi-vetmedica.com.
####
Boehringer Ingelheim News Release page 4 of 4